Legislation & Regulation
Richard Mark Kirkner

Gary Claxton, Kaiser Family Foundation

Only 11 of the not-for-profit health plans are still operating, and the program that would cushion them from financial losses is in trouble. Will it be fixed?

Medication Management

Pharmaceutical companies still hold important cards when it comes to negotiating prices, but that may change with new ways of measuring value.

Cancer Watch
Peter Wehrwein

James Helstrom, CMO of Fox Chase Cancer Center

The country’s elite cancer hospitals may be facing a less coddled existence. Fox Chase is getting ahead of the game with efforts to reduce readmissions.
Tomorrow's Medicine
Thomas Morrow, MD

At last there is a treatment for the inherited condition that affects bone development. But at $300,000 per year, cost is a major issue.

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report